TY - CONF
T1 - 52-week laboratory safety findings from an open-label extension (OLE) study of dupilumab in adolescent patients with atopic dermatitis (LIBERTY AD PED-OLE)
JO - JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
PY - 2021/01/01
AU - Cork MJ
AU - Lockshin B
AU - Blauvelt A
AU - Chen Z
AU - Khokhar FA
AU - Bansal A
AU - Prescilla R
ED -
VL - 85
IS - 3
SP - AB120
EP - AB120
Y2 - 2025/01/01
ER -